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Abstract
Background: The benefits of new innovations in glioblastoma therapies should not be curtailed as a result of
delays in commencement of radiation therapy, caused by clinical circumstances as well as diagnostic procedures.
This study evaluates whether delays in chemo-radiotherapy after surgery, while determining O6-methylguanine-
DNA-methyltransferase (MGMT) promoter status, affect the survival rates of patients with glioblastoma (GBM).
Methods: Our sample comprised 50 GBM patients in a retrospective analysis of three prospective studies that
focused on combined radiotherapy and required MGMT promoter-status testing as inclusion criteria. Results were
compared with a reference group of 127 favourable GBM cases (Karnofsky performance-status scale≥ 70), in which the
patients underwent standard postoperative chemo-radiotherapy with temozolomide. Survival time was calculated
using the Kaplan-Meier method, and a multivariate analysis of the delays between surgical and radiotherapy
procedures was performed using the Cox regression model.
Results: The study group’s median overall survival time was 16.2 months (with a range of 2 to 56 months), versus the
reference group’s survival time of 18.2 months (with a range of 1 to 92 months) (p = 0.64). The delay between surgery
and radiotherapy was increased by 8 days in the study patients (p < 0.001), with a median delay of 35 days (range:
18–49 days) corresponding to the typical 27-day delay (range: 5–98 days) for those in the reference group. Univariate
and multivariate analyses did not show any negative association between survival time and delaying radiation therapy
to determine MGMT-promoter status; commencement of radiation therapy sooner than 24 days after surgery was the
threshold for significantly decreased overall survival (p = 0.01) and progression-free (p = 0.03) survival.
Conclusion: Delaying postoperative chemoradiation for GBM patients—carried out in order to determine MGMT-promoter
status—did not have a negative impact on survival time. Indeed, the data of the present study shows that initiating
radiation therapy sooner than 24 days after surgery has a negative impact on progression and survival.
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Background
GBM is the most common type of primary brain tumours
in adults. Standard therapy for this type of cancer consists
of maximum surgical resection, followed by postoperative
temozolomide-based (TMZ-based) chemoradiation [1].
And yet, survival time—with a median of around 15 month-
s—is still unsatisfactory for this therapy regimen [1].
Despite the discovery of new therapeutic approaches,
delayed initiation of treatment has been shown to have a
negative impact on survival rates; this hypothesis has
recently garnered renewed attention, as data on other
tumour types (e.g. breast cancer [2–4], head and neck
cancer [4, 5], and small-cell lung cancer [6, 7]) have sup-
ported it. The mechanisms underlying this phenomenon
are still not entirely understood. The physical effects of
treatment delay—including early, local recurrence and
distant relapse—might be described as increasing in
probability as a function of time [8]. It seems obvious
that effects might be more pronounced in fast-growing
tumours with short doubling times [8].
Because GBMs are highly aggressive, quickly proliferating
tumours, the connection between delay in radiotherapy
and decreased survival for GBM patients has led to the
general practice of initiating treatment about 2 to 4 weeks
after surgery. One can expect further progression to be
severely affected by a delay in treatment initiation [8, 9].
Previous studies implicate delayed radiotherapy in a signifi-
cant reduction of survival times for high-grade glioma
patients [10, 11].
Hence, GBM progression—with its aggressive charac-
teristics—may be highly receptive to the negative effects
caused by delays in initiation of treatment. And yet,
there are many potential reasons for delaying treatment,
including surgical complications, limited resources, and
comorbidities.
Longer delays in initiation of treatment can also be
linked to elaborate, highly advanced treatment regimens
(e.g. time is needed to determine molecular markers).
These markers and their activation statuses have been
known to stratify into different treatment groups. For
GBM, MGMT-promoter methylation is known to influ-
ence survival after chemoradiation with TMZ. That is
why several studies based on this stratification factor
have already been performed [12].
However, determination of the MGMT-promoter methy-
lation status is difficult [13] and time-consuming. Several
European Organisation for Research and Treatment of
Cancer (EORTC) studies have recently been conducted to
evaluate new therapeutic approaches connected to MGMT
methylation status [14].
The present study evaluates a large number of GBM
patients treated with TMZ chemoradiation and ana-
lyses how differing times between their surgeries and
treatments affected their outcomes. The aim of this
analysis is to show whether increasing the span of time
between surgery and chemoradiation in order to de-
termine MGMT-promotor methylation status has a
potentially detrimental effect on outcomes.
Methods
Study-population selection
Subjects for this study’s analysis were identified using an
in-house radiation-oncology brain-tumour database. The
study group consisted of 50 patients treated with chemo-
radiation for histologically proven GBM in multicentre
clinical trials (Table 1) at Heidelberg University Hospital’s
Department of Radiation Oncology. The main eligibility
criteria for this study included those patients who have
undergone chemoradiation. Thus, the data are based on a
well-characterized and homogeneous population. Next,
the MGMT-promoter methylations of the 50 patients in
the present study’s sample were compared with those of
223 GBM patients whom the aforementioned Radiation
Oncology Department treated primarily with chemoradio-
therapy between January 2004 and December 2011.
To account for its more selective sampling, the present
study only focused on a favourable patient reference group
(n = 127), with a Karnofsky performance-status scale
(KPS) ≥70.
MGMT-promoter methylation status was assessed
using a methylation-specific (MSP) chain reaction, as
previously described [15]. KPS was determined before
initiating radiation therapy.
Study-group treatment regimens
Result summaries for the three clinical trials used in the
present study are depicted in Table 1. Prior to randomi-
zation and result measurements, written, informed con-
sent was obtained from each participating patient. In all
three studies, conventional, 3D-conformal fractionated
radiotherapy was performed, and the protocols of all
three studies, as well as the current retrospective study
(Nr. S-056/2015) were approved by Heidelberg Univer-
sity Hospital’s ethics committee. All studies were per-
formed in accordance with local laws and the Helsinki
Declaration and written informed consent was obtained
for all study patients.
Chemoradiotherapy for the reference group
Conventional, 3D-conformal fractionated radiotherapy
for the reference group was performed as previously
described, with a median dose of 60.0 Gy [16]. For
purposes of planning treatment, patients were fixed
with custom-made masks, and computed tomography
and MRI imaging were performed. Several fraction-
ation schemes were used during the investigation
period. Three dimensional-conformal radiation ther-
apy was used on all patients included in the current
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study. Additionally, patients received concomitant TMZ
administration in accordance with the Stupp scheme [1].
Imaging procedures
Initial MRIs, treatment-planning CTs and MRIs, and
follow-up MRIs served as disease-evaluation tests for the
entire sample. Tumour localization and progression were
determined on the basis of contrast-enhanced, T1-weighted
sequences on axial and coronal images. Images were ad-
judged and reviewed by experienced radiological specialists
(T. W. and T. B.).
Clinical hospital course records and pre- and post-
operative MRI imaging were evaluated in accordance
with institutional guidelines. The time interval between
surgery and radiotherapy was calculated in days from
the last day of surgical treatment to the first day of
radiotherapy. Survival was measured from the date of
initial surgical resection to disease progression and last
follow-up or death.
Progression-free survival (PFS) was calculated as the
timespan between the first day of radiation therapy and
the occurrence of local or distant progression, determi-
nations of which were based on contrast-enhanced,
T1-weighted MRI scans (axial and coronal) as per
RANO criteria. If the radiologist suspected pseudo-
progression, further follow-up MRIs were obtained to
verify true radiographic progression [17]. Progression
analysis data were censored when death occurred
without MRI-determined progression, or without a
follow-up examination.
Survival analyses were performed using the Kaplan-Meier
method. A comparison between the two subgroups was
undertaken using the log-rank analysis method. Variable
patient characteristics were compared using odds ratios,
the χ2 test, the Cox regression model, and corresponding
95 % confidence intervals. The threshold significance level
was p < 0.05.
Results
Patient characteristics are listed in Table 2. The refer-
ence group showed an insignificantly higher ratio of
patients (OR = 1.5; 95 % CI: 0.77–2.93; p = 0.32) who
underwent gross-total surgical resection (n = 58;
45.7 %), in contrast with the study group (n = 18;
36.0 %). Biopsies for pathological confirmation with no
further surgery were performed on nine patients (7.1 %)
in the reference group and two patients (4.0 %) in the
study group. No difference was observed in the compos-
ition of both treatment groups in terms of pre-
therapeutic, multifocal GBM occurrence (OR = 0.70;
95 % CI: 0.28–1.91; p = 0.63).
The median survival time for all patients in the study
was 16.2 months (with a range of 2 to 56 months),
versus a survival time of 18.2 months (with a range
from 1 to 92 months) for participants in the reference
group (p = 0.64). There was no significant, verifiable dif-
ference in both groups’ progression-free survival (PFS)
(6.9 vs. 6.3 months; p = 0.20).
In analysing the impact of surgical-resection status
on outcome—bearing in mind the higher proportion of
Table 1 Study protocols and included patient numbers
Designs of the analyzed prospective studies
Study Phase Treatment regimens MGMT promoter
status
Absolut
patient
numbers
TEMSIROLIMUS
(EORTC 26082–22081)
III 1. Conventional RT with 60 Gy plus temsirolimus 25 mg once a week beginning
7 days before initiation of radiotherapy. Adjuvant cycles of temsirolimus
25 mg once a week until progression.
Unmethylated 19
2. Conventional RT with 60 Gy plus 75 mg/m2/d TMZ during RT. Up to six cycles
of adjuvant TMZ for 5 days every 28 days with 150 mg/m2/d for the first
adjuvant cycle and 200 mg/m2/d for the following cycles.
ENZASTAURIN
(H6Q-MC-S039)
II 1. Conventional RT with 60 Gy plus Enzastaurin 250 mg b.i.d. until progression or
a maximum of 3 years.
Unmethylated 13
2. Conventional RT with 60 Gy plus 75 mg/m2/d TMZ during RT. Up to six cycles
of adjuvant TMZ for 5 days every 28 days with 150 mg/m2/d for the first adjuvant
cycle and 200 mg/m2 for the following cycles.
CENTRIC
(EORTC 26071–22072)
III 1. Conventional RT with 60 Gy plus 75 mg/m2/d TMZ during RT plus Cilengitide 2000 mg
twice a week beginning 7 days before initiation of radiotherapy until day 77 or
progression. Up to six cycles of adjuvant TMZ for 5 days every 28 days with
150 mg/m2/d for the first adjuvant cycle and 200 mg/m2/d for the following cycles.
Methylated 18
2. Conventional RT with 60 Gy plus 75 mg/m2/d TMZ during RT. Up to six cycles
of adjuvant TMZ for 5 days every 28 days with 150 mg/m2/d for the first adjuvant
cycle and 200 mg/m2/d for the following cycles.
Abbreviations: MGMT = O6-methylguanine-DNA methyltransferase; TMZ = Temozolomide; mg =Milligram; m =Meter; d = Day, RT = Radiation Therapy
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patients in the reference group who underwent gross-
total resection—the present study compared patients in
the reference group after complete (n = 58; 45.7 %) or
partial resection (n = 60; 47.2 %) with patients in the
study group (n = 18; 36.0 % and n = 30; 60.0 %; OR:
1.61, p = 0.17) with regard to overall survival (OS) and
PFS. No difference in survival rates was found between
subtotal-resected patients in the study group (OS:
17.0 months; range: 2.1–55.6 months) and the reference
group (OS: 15.4 months; range: 2.7–87.7 months) with
p = 0.47. Accordingly, there was no significant differ-
ence (p = 0.84) in the survival rates of total-resected
patients in the study group (OS: 15.8 months; range:
7.3–47.0 months) and the reference group (OS:
22.3 months; range: 2.5–91.7). Study medication did not
affect PFS (p = 0.59) or OS (p = 0.88) in the study group.
Interestingly, the results of the present study showed a
statistically significant difference in outcomes for the two
groups, based on the differing time intervals between sur-
gery and the start of radiotherapy (p < 0.001). The median
delay between these two treatments for study patients
was 35 days (with a range of 18 to 49 days), versus the
reference-sample patients’ median delay of 27 days (range:
5–98 days). The median additional delay for MGMT-
promoter determination was 8 days (with a range of
3 to 34 days). MGMT methylation status significantly
influenced OS in the reference group (methylated:
25.2 months vs. non-methylated: 15.4 months; p = 0.04),
whereas this, in no way, influenced survival for the study
group (p = 0.129). The results of this study’s univariate
and multivariate analyses are shown in Tables 3, 4
and 5. Delay was found to have had no significant nega-
tive effects on OS and PFS. However, delaying radiother-
apy had a significant protective effect on death rates,
with a Hazard ratio of 0.95 (95 % CI: 0.90–1.00; p =
0.044) (Table 5). Interestingly, this study’s authors ob-
served a threshold for decreased progression-free and
overall survival in both groups if radiotherapy was per-
formed earlier than 24 days after surgery.
Discussion
This study found an 8-day increase in the median time
interval between surgery and the initiation of radiotherapy
due to MGMT-promoter methylation determination.
However, its results showed that delaying radiation ther-
apy to determine MGMT-promoter methylation did not
have a significantly negative impact on patients’ survival.
Interestingly, study participants actually exhibited a de-
creased likelihood of death in dependency-of-treatment
delay (HR: 0.95; p = 0.045). Thus, initiating RT earlier
than 24 days after surgery was associated negatively
with overall survival.
The association between delaying radiation and decreased
survival, as well as higher loco-regional recurrence rates,
has been examined most extensively for head-and-neck,
breast, and small cell-lung cancers [2–7]. Unfortunately,
contradictory findings have been reported for GBM. Time
delays between GBM patients’ undergoing surgical proce-
dures and radiotherapy at Heidelberg University Hospital’s
Table 3 Univariate proportional-hazards regression analysis of
cofactors on progression-free survival in glioblastoma patients
Cofactors HR 95 % CI P value
Study group
Age <60 years 0.73 0.39–1.35 0.31
Karnofsky Performance Status >70 0.65 0.25–1.67 0.37
Resection 0.24 0.03–1.92 0.18
Gross Total Resection 0.91 0.48–1.74 0.77
Study medication 1.19 0.63–2.26 0.59
MGMT promoter methylation 1.23 0.64–2.35 0.54
Reference group
Age <60 years 1.07 0.70–1.64 0.76
Karnofsky Performance Status >70 n.e. n.e. n.e.
Resection 1.27 0.47–3.48 0.64
Gross total Resection 0.85 0.56–1.29 0.45
MGMT promoter methylation 0.35 0.15–0.86 0.02
Abbreviations: CI = Confidence interval; HR = Hazard ratio; SVZ =
Subventricularzone; MGMT = O6-methylguanine-DNA methyltransferase
Table 2 Patient characteristics of the study group and reference
group
Study group
in absolut
numbers (%)
Reference group
in absolut
numbers (%)
Gender
Female 16 (32) 45 (35.4)
Male 34 (68) 82 (64.6)
Age in years [range] 58,9 [30.3–75.9] 58.7 [20.3–75.5]
Median KPS [range] 90 [60–100] 90 [70–100]
MGMT-promoter-status
MGMT-status not determined 0 (0) 95 (74.8)
MGMT-status determined 50 (100) 32 (25.2)
MGMT-promoter methylated 18 (36) 14 (43.8)
MGMT-promoter not methylated 32 (64) 18 (56.2)
Resection status
Gross Total resection 18 (36) 58 (45.7)
Subtotal resection 30 (60) 60 (47.2)
Biopsy 2 (4) 9 (7.1)
Temozolomide therapy 26 (52) 127 (100)
Study medication 33 (66) n.e.
Median delay to RT in days [range] 35 [18–49] 27 [5–98]
Abbreviations: MGMT: O6-methylguanine-DNA-methyltransferase, KPS: Karnofsky
performance status; RT: Radiation therapy
Numbers in parentheses (*) are the percentages
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Department of Radiation Oncology is usually about 3 to 5
weeks; nevertheless, the ideal time interval is yet to be
determined. A study published in 2000 first explicitly
evaluated the effects of radiotherapy delays on the pro-
gression of high-grade glioma. In a single institutional
trial, the authors reported that waiting for radiotherapy
had a negative impact on patient survival rates and risk
of death increased by 2 % for every day radiation ther-
apy was delayed. This earlier study’s sample comprised
182 GBM patients who were subject to a median delay
of 26 days [18], and its findings should be considered
with some degree of reservations because of the 2007
revisions to the neuropathological classifications [19]
and because it selected its sample-patient population by
removing favourable prognostic cases [18]. Indeed,
Thomson et al. found no relationship between delaying
radiation therapy and treatment outcomes for GBM
patients [20]. Likewise, a review of 16 RTOG-study
populations, comprising 2855 GBM patients, could not
find any evidence of reduced survival rates caused by
increased wait times (up to 6 weeks) for radiotherapy.
Still, patients who started radiotherapy more than 4
weeks after surgery showed a significant survival advan-
tage when compared with those who began radiation
therapy within 14 days of undergoing surgery. These
unexpected findings might be explained by the fact that
postoperative radiotherapy is typically initiated more
immediately for advanced tumours, thus contributing to
the larger number of patients in the sample with KPS ≤
70. Hence, there was an overrepresentation of study-
group patients who only underwent biopsies for GBM
confirmation [21]. A similar approach might explain the
results of the present study, which showed decreased
survival rates for those who underwent radiation therapy
sooner than 24 days after surgery: physicians might simply
initiate radiation therapy sooner for more pronounced
cases of GBM. And yet, median KPS for this subgroup in
the present study’s sample was 90. Commencing radiation
therapy later than the abovementioned 24 days might,
therefore, seem to have served as a protective factor. It
seems obvious, though, that those with highly prolific
tumours, like GBM, should receive post-operative radi-
ation therapy as soon as possible. Therefore, unnecessar-
ily delaying radiation therapy should be avoided, even
though the present study’s results do not state this;
previous data also suggest radiation therapy in cases
of malignant supratentorial glioma should take place
no later than 37 days after surgical resection. Prolong-
ing wait times further than this has led to significant
decreases in overall survival rates [22].
Interestingly, Irwin et al. found a statistically significant
increase in death rates (8.9 %) for every additional week
between surgery and radiotherapy. It should also be noted
that around 50 % of patients experienced a treatment
delay of 5 weeks or more, due to personal and financial
constraints. In fact, disproportionate radiotherapy delays
might explain diminished survival rates [10]. To be sure,
the data of this study did not show that such delays
negatively impacted survival for members of its own
Table 5 Univariate proportional-hazards regression analysis of the influence of treatment delay on progression-free and overall survival
in glioblastoma patients
Group Survival Covariate HR 95 % CI Significance level
Study group OS Time delay to RT 0.95 0.90–0.99 0.04
Reference group OS Time delay to RT 0.99 0.98–1.00 0.13
Study group PFS Time delay to RT 0.97 0.93–1.01 0.18
Reference group PFS Time delay to RT 1.00 0.98–1.01 0.59
Study group OS Time delay to RT ≥24 days 0.43 0.23–0.83 0.01
Reference group OS Time delay to RT ≥24 days 0.59 0.40–0.89 0.01
Study group PFS Time delay to RT ≥24 days 0.49 0.26–0.92 0.03
Reference group PFS Time delay to RT ≥24 days 0.62 0.40–0.96 0.03
OS: Overall survival; PFS: Progression-free survival; HR: Hazard ratio; CI: Confidence interval; RT: Radiation therapy
Table 4 Univariate proportional-hazards regression analysis of
cofactors on overall survival in glioblastoma patients
Cofactors HR 95 % CI P value
Study group
Age <60 years 1.18 0.62–2.25 0.62
Karnofsky Performance Status >70 1.00 0.35–2.84 0.99
Resection 0.81 0.44–1.54 0.72
Gross Total Resection 1.09 0.56–2.12 0.81
Study medication 0.95 0.48–1.87 0.88
MGMT promoter methylation 0.63 0.31–1.27 0.19
Reference group
Age <60 years 0.78 0.27–2.61 0.73
Karnofsky Performance Status >70 n.e. n.e. n.e.
Resection 0.81 0.35–1.85 0.61
Gross Total Resection 0.75 0.50–1.12 0.16
MGMT promoter methylation 0.43 0.18–0.99 0.048
Abbreviations: CI = Confidence interval; HR = Hazard ratio; SVZ = Subventricular
zone; MGMT = O6-methylguanine-DNA methyltransferase
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sample or those in its reference sample. Yet, the short
delays for persons in the sample of the present study
(with a median of 5 weeks and a range of 1 to 7 weeks)
make it difficult to draw comparisons. It is as yet unclear,
at any rate, if the delays to RT caused by histological exami-
nations and new technologies—as were mandatory for en-
rolment in the utilized studies—negatively impact survival.
Also notable in all three examined studies were the
applications of new therapeutic approaches that used
cytotoxic and immune-modulating agents. Therapeutic
advances should not, therefore, be relativized to clinical
circumstances, such as time delays for MGMT-promoter
determination, as mandated by this study’s inclusion
criteria. The present study’s authors must emphasize the
creation of reference groups that suit inclusion criteria.
To minimize potential bias by varying patient character-
istics KPS ≥ 70, resection status, and concomitant TMZ
therapy were selected to create two consistent groups
and facilitate comparison. However, no study has been
designed to evaluate delays between surgical resection
and the initiation of radiotherapy. The majority of study
patients received a study medication, whereas the refer-
ence group was given TMZ therapy, and this might have
caused biased results. Still, the application of study medi-
cation was not associated with patient survival. And,
although the present data suffers from the potential bias
and usual shortcomings inherent in retrospective study
designs, prospective trials evaluating the relationship be-
tween delays and survival are not practical.
Finally, the premature commencement of radiotherapy
after surgical procedures might be counterproductive,
and radio-sensitivity is likely to be diminished by hyp-
oxia and oedematous areas in the surgical site [21].
Technical innovations offer new approaches for treating
the GBM; paradoxically, recent steps that subtly lengthen
the interval between surgery and the commencement
of radiation therapy do not seem to endanger therapy
success.
Conclusion
Granting the inherent limitations of retrospective analyses,
the present study found that delays between surgery and
radiation treatment for GBM patients, as caused by
MGMT-promoter determination, were not disadvanta-
geous; rather, starting radiation therapy sooner than
24 days after surgery was an independent negative prog-
nostic survival factor. And yet, these findings only reflect
data from patients whose radiation therapy was initiated
within 7 weeks after surgery. Logic dictates that delaying
treatment beyond a certain point will negatively influence
survival, but this was not examined in the present study.
Determining the optimal delay between surgery and radi-
ation therapy is, therefore, of great interest, and merits
further investigation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JD, SC and WW treated the patients. SA, SH and DB made the data
collection. SA is responsible for statistical considerations of the analysis. TB
and TW are responsible for the radiographic assessment. All authors read
and approved the final manuscript.
Acknowledgements
The authors thank all of the study participants. We would also like to thank
Sabine Kuhn and her team of radiation technologists for their excellent work.
We acknowledge financial support by Deutsche Forschungsgemeinschaft
and Ruprecht-Karls-Universität Heidelberg within the funding program Open
Access Publishing.
Author details
1Department of Radiation Oncology, University Hospital of Heidelberg,
Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. 2Heidelberg
Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg,
Germany. 3Clinical Cooperation Unit Radiation Oncology, German Cancer
Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg,
Germany. 4Department of Neurooncology, University Hospital of Heidelberg,
Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. 5Department of
Radiation Oncology, Klinikum rechts der Isar, Technische Universität
München, Ismaninger Str. 22, 81675, München, Germany.
Received: 7 April 2014 Accepted: 14 July 2015
References
1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ,
et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 2005;352(10):987–96.
2. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence
of delay on survival in patients with breast cancer: a systematic review.
Lancet. 1999;353(9159):1119–26.
3. Buchholz TA, Austin-Seymour MM, Moe RE, Ellis GK, Livingston RB, Pelton
JG, et al. Effect of delay in radiation in the combined modality treatment of
breast cancer. Int J Radiat Oncol Biol Phys. 1993;26(1):23–35.
4. Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship
between waiting time for radiotherapy and clinical outcomes: a systematic
review of the literature. Radiother Oncol. 2008;87(1):3–16.
5. Barton MB, Morgan G, Smee R, Tiver KW, Hamilton C, Gebski V. Does
waiting time affect the outcome of larynx cancer treated by radiotherapy?
Radiother Oncol. 1997;44(2):137–41.
6. Lee AW, Chan DK, Fowler JF, Poon YF, Law SC, Foo W, et al. T1
nasopharyngeal carcinoma: the effect of waiting time on tumor control. Int
J Radiat Oncol Biol Phys. 1994;30(5):1111–7.
7. Choi N, Baumann M, Flentjie M, Kellokumpu-Lehtinen P, Senan S,
Zamboglou N, et al. Predictive factors in radiotherapy for non-small cell
lung cancer: present status. Lung Cancer. 2001;31(1):43–56.
8. Mackillop WJ, Bates JH, O’Sullivan B, Withers HR. The effect of delay in
treatment on local control by radiotherapy. Int J Radiat Oncol Biol Phys.
1996;34(1):243–50.
9. Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C, Clinical
Significance Consensus Meeting G. Assessing the clinical significance of
single items relative to summated scores. Mayo Clinic proceedings Mayo
Clinic. 2002;77(5):479–87.
10. Irwin C, Hunn M, Purdie G, Hamilton D. Delay in radiotherapy shortens
survival in patients with high grade glioma. J Neurooncol.
2007;85(3):339–43.
11. Gonzalez-SanSegundo C, Santos-Miranda JA, Cuesta-Alvaro P. Comment on:
The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother
Oncol. 2001;60(3):333–4.
12. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of
O6-methylguanine methyltransferase (MGMT) promoter methylation with
clinical outcomes in glioblastoma and clinical strategies to modulate MGMT
activity. J Clin Oncol. 2008;26(25):4189–99.
Adeberg et al. BMC Cancer  (2015) 15:558 Page 6 of 7
13. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W,
et al. MGMT promoter methylation in malignant gliomas: ready for
personalized medicine? Nat Rev Neurol. 2010;6(1):39–51.
14. Wick W, Steinbach JP, Platten M, Hartmann C, Wenz F, von Deimling A,
et al. Enzastaurin before and concomitant with radiation therapy, followed
by enzastaurin maintenance therapy, in patients with newly diagnosed
glioblastoma without MGMT promoter hypermethylation. Neuro Oncol.
2013;15(10):1405–12.
15. Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I,
et al. Validation of real-time methylation-specific PCR to determine
O6-methylguanine-DNA methyltransferase gene promoter methylation in
glioma. JMD. 2008;10(4):332–7.
16. Adeberg S, Konig L, Bostel T, Harrabi S, Welzel T, Debus J, et al.
Glioblastoma recurrence patterns after radiation therapy with regard to the
subventricular zone. Int J Radiat Oncol Biol Phys. 2014;90(4):886–93.
17. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E,
et al. Updated response assessment criteria for high-grade gliomas:
response assessment in neuro-oncology working group. J Clin Oncol.
2010;28(11):1963–72.
18. Do V, Gebski V, Barton MB. The effect of waiting for radiotherapy for grade
III/IV gliomas. Radiother Oncol. 2000;57(2):131–6.
19. Scheithauer BW, Fuller GN, VandenBerg SR. The 2007 WHO classification of
tumors of the nervous system: controversies in surgical neuropathology.
Brain Pathol. 2008;18(3):307–16.
20. Thomson CL, Watterson A, Pritchard C, Thomson AH. Effects of waiting
times and adjuvant radiotherapy in patients with glioblastoma multiforme.
Clin Oncol. 2007;19:47–8.
21. Blumenthal DT, Won M, Mehta MP, Curran WJ, Souhami L, Michalski JM,
et al. Short delay in initiation of radiotherapy may not affect outcome of
patients with glioblastoma: a secondary analysis from the radiation therapy
oncology group database. J Clin Oncol. 2009;27(5):733–9.
22. Glinski B, Urbanski J, Hetnal M, Malecki K, Jarosz M, Mucha-Malecka A, et al.
Prognostic value of the interval from surgery to initiation of radiation
therapy in correlation with some histo-clinical parameters in patients with
malignant supratentorial gliomas. Contemp Oncol. 2012;16(1):34–7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Adeberg et al. BMC Cancer  (2015) 15:558 Page 7 of 7
